Logo

Chemicon Enters Gene-Targeting Agreement with Genome Biosciences

Nov 18, 2003

NEW YORK, Nov. 18 (GenomeWeb News) - Chemicon International, a division of Serologicals, said today that it has entered into an exclusive licensing agreement for Genome BioSciences' Positive-Positive Selection (PPS) gene-targeting technology.

Under the agreement, Chemicon will have the exclusive right to use the PPS technology for generating genetically modified cell lines and mice for its customers. Chemicon said it will also retain exclusive rights to grant third-party technology sublicenses to the PPS technology.

In addition, Rob Burgess, Genome BioSciences President, will join Chemicon as senior director of functional genomics while remaining a director of Genome BioSciences.

Financial terms of the licensing agreement were not disclosed.

Chemicon said that Genome BioSciences' technology is "the first in a series of platform technologies" it expects to license in support of a new functional genomics initiative at the company.

Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.